Journal
CANCER
Volume 123, Issue 18, Pages 3434-3440Publisher
WILEY
DOI: 10.1002/cncr.30757
Keywords
adolescent; clinical trials; National Clinical Trials Network; sarcoma; young adult
Categories
Funding
- National Clinical Trials Network [U10CA180886, U10CA180899]
- National Cancer Institute through a Specialized Program of Research Excellence grant [U54CA168512]
- Quad W Foundation
- Sarcoma Foundation of America
- US Department of Defense
- Novartis
- Aventis
- Eli Lilly
- Bristol-Myers Squibb
- Hoffmann-La Roche
- AstraZeneca
- Synta
- Tesaro
- Merck
Ask authors/readers for more resources
More than half of all sarcomas occur in adolescents and young adults (AYAs) aged 15 to 39 years. After the publication of the AYA series in the April 1, 2016 issue of Cancer, several leaders in the field of sarcoma across disciplines gathered to discuss the status of sarcoma clinical research in AYAs. They determined that a focused effort to include the underrepresented and understudied AYA population in current and future sarcoma clinical trials is overdue. Trial enrichment for AYA-aged sarcoma patients will produce more meaningful results that better represent the disease's biology, epidemiology, and treatment environment. To address the current deficit, this commentary outlines changes believed to be necessary to expediently achieve an increase in the enrollment of AYAs in sarcoma clinical trials. Cancer 2017;123:3434-40. (c) 2017 American Cancer Society.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available